

20044, and should refer to *United States v. Rhode Island Waste Management Corporation*, D.J. Ref. 90-11-2-827.

The proposed Consent Decree may be examined at the Region 1 Office of the Environmental Protection Agency, One Congress Street, Boston Massachusetts. Copies of the Consent Decree may be examined at the Environmental Enforcement Section Document Center, 1120 G Street, N.W., 4th Floor, Washington D.C. 20005, (202) 624-0892. A copy of the proposed Consent Decree may be obtained in person or by mail from the Document Center. In requesting a copy, please refer to the referenced case and enclose a check in the amount of \$26.25 (25 cents per page reproduction cost, excluding appendices) made payable to Consent Decree Library.

Joel M. Gross,

*Section Chief, Environmental Enforcement Section.*

[FR Doc. 96-19404 Filed 7-30-96; 8:45 am]

BILLING CODE 4410-01-M

#### Antitrust Division

##### Notice Pursuant to the National Cooperative Research and Production Act of 1993—Petroleum Environmental Research Forum Project No. 95-12

Notice is hereby given that, on July 1, 1996, pursuant to Section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. § 4301 *et seq.* ("Act"), the Petroleum Environmental Research Forum ("PERF") Project No. 95-12, titled "Monitoring of Composting and Soil Bioremediation", has filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing (1) the identities of the parties and (2) the nature and objectives of the venture. The notifications were filed for the purpose of invoking the Act's provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances. Pursuant to Section 6(b) of the Act, the identities of the parties are: Chevron Research and Technology Company, Richmond, CA; BP Oil Company, Cleveland, OH; Exxon Production Research Company, Houston, TX; and Atlantic Richfield Company, Plano, TX. The nature and objective of this project is to improve the methods that can be used to monitor composting and soil bioremediation projects. Research and development work required in furtherance of the project is to be carried out by Bioremediation Consulting, Inc.

Participation in this project will remain open to interested persons and

organizations until the Project Completion Date, which is presently anticipated to occur approximately August 31, 1997, but no later than December 31, 1998. The participants intend to file additional written notifications disclosing all changes in its membership. Information regarding participation in the project may be obtained from Ms. Sara J. McMillen, Chevron Research and Technology Company, 100 Chevron Way, Richmond, CA 94802-1627, telephone (510) 242-3485, Fax (510) 242-1954.

Constance K. Robinson,

*Director of Operations Antitrust Division.*

[FR Doc. 96-19396 Filed 7-30-96; 8:45 am]

BILLING CODE 4410-01-M

#### Drug Enforcement Administration

##### Importation of Controlled Substances; Notice of Application

Pursuant to Section 1008 of the Controlled Substances Import and Export Act (21 U.S.C. 958(i)), the Attorney General shall, prior to issuing a registration under this Section to a bulk manufacturer of a controlled substance in Schedule I or II and prior to issuing a regulation under Section 1002(a) authorizing the importation of such a substance, provide manufacturers holding registrations for the bulk manufacture of the substance an opportunity for a hearing.

Therefore, in accordance with Section 1311.42 of Title 21, Code of Federal Regulations (CFR), notice is hereby given that on July 9, 1996, Bridgeway Trading Corporation, 7401 Metro Blvd., Suite 480, Minneapolis, Minnesota 55439, made application to the Drug Enforcement Administration to be registered as an importer of marihuana (7360) a basic class of controlled substance listed in Schedule I.

The firm plans to import marihuana seed which will be rendered non-viable and used as bird food.

Any manufacturer holding, or applying for, registration as a bulk manufacturer of this basic class of controlled substance may file written comments on or objections to the application described above and may, at the same time, file a written request for a hearing on such application in accordance with 21 CFR 1301.54 in such form as prescribed by 21 CFR 1316.47.

Any such comments, objections, or requests for a hearing may be addressed to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, United States Department of Justice,

Washington, D.C. 20537, Attention: DEA Federal Register Representative (CCR), and must be filed no later than (30 days from publication).

This procedure is to be conducted simultaneously with and independent of the procedures described in 21 CFR 1311.42(b), (c), (d), (e), and (f). As noted in a previous notice at 40 FR 43745-46 (September 23, 1975), all applicants for registration to import basic classes of any controlled substances in Schedule I or II are and will continue to be required to demonstrate to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration that the requirements for such registration pursuant to 21 U.S.C. 958(a), 21 U.S.C. 823(a), and 21 CFR 1311.42 (a), (b), (c), (d), (e), and (f) are satisfied.

Dated: July 25, 1996.

Gene R. Haislip,

*Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.*

[FR Doc. 96-19442 Filed 7-30-96; 8:45 am]

BILLING CODE 4410-09-M

##### Manufacturer of Controlled Substances; Notice of Application

Pursuant to Section 1301.43(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on April 29, 1996, Guilford Pharmaceuticals, Inc., Attn: Ross S. Laderman, 6611 Tributary Street, Baltimore, Maryland 21224, made application to the Drug Enforcement Administration (DEA) for registration as a bulk manufacturer of the Schedule II controlled substance cocaine (9041).

The firm plans to manufacture methyl-3-beta-(4-trimethylstannylphenyl)-tropane-2-carboxylate as a final intermediate for the production of dopascan injection.

Any other such applicant and any person who is presently registered with DEA to manufacture such substances may file comments or objections to the issuance of the above application.

Any such comments or objections may be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, United States Department of Justice, Washington, D.C. 20537, Attention: DEA Federal Register Representative (CCR), and must be filed no later than September 30, 1996.